NASDAQ:STRO Sutro Biopharma Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.21 -0.03 (-0.57%) (As of 06/30/2022 12:00 AM ET) Add Compare Share Today's Range$5.05▼$5.3750-Day Range$3.41▼$7.4052-Week Range$3.33▼$23.70Volume1.60 million shsAverage Volume777,630 shsMarket Capitalization$244.53 millionP/E RatioN/ADividend YieldN/APrice Target$24.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive STRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address STRO Stock Forecast (MarketRank)Overall MarketRank™1.98 out of 5 starsMedical Sector625th out of 1,433 stocksBiological Products, Except Diagnostic Industry102nd out of 217 stocksAnalyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingSutro Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.33, Sutro Biopharma has a forecasted upside of 367.1% from its current price of $5.21.Amount of Analyst CoverageSutro Biopharma has only been the subject of 2 research reports in the past 90 days. Previous Next 4.1 Community Rank Outperform VotesSutro Biopharma has received 95 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSutro Biopharma has received 59 “underperform” votes. (Add your “underperform” vote.)Community SentimentSutro Biopharma has received 61.69% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Sutro Biopharma and other stocks. Vote “Outperform” if you believe STRO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe STRO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSutro Biopharma does not currently pay a dividend.Dividend GrowthSutro Biopharma does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sutro Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.10% of the stock of Sutro Biopharma is held by insiders.Percentage Held by Institutions92.68% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sutro Biopharma are expected to decrease in the coming year, from ($3.27) to ($3.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sutro Biopharma is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sutro Biopharma is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSutro Biopharma has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sutro Biopharma (NASDAQ:STRO)Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.Read More STRO Stock News HeadlinesJune 29, 2022 | benzinga.comShort Volatility Alert: Sutro Biopharma, Inc.June 28, 2022 | marketwatch.comSutro Biopharma Shares Rise 24% After Collaboration With Astellas PharmaJune 28, 2022 | finance.yahoo.comSutro Biopharma Stock Surges On Cancer Treatment PactJune 28, 2022 | nasdaq.comAstellas, Sutro Collaborate To Advance Novel Immunostimulatory Antibody-Drug ConjugatesJune 28, 2022 | seekingalpha.comSutro Biopharma gains nearly double after announcing worldwide strategic collaboration with Astellas PharmaJune 27, 2022 | marketwatch.comSutro Biopharma Shares Soar 67% on Cancer Treatment Collaboration with AstellasJune 27, 2022 | finance.yahoo.comAstellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)June 27, 2022 | finance.yahoo.comAstellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)June 7, 2022 | msn.comSutro Biopharma's Return On Capital Employed InsightsJune 7, 2022 | americanbankingnews.comSutro Biopharma (NASDAQ:STRO) Given "Buy" Rating at JMP SecuritiesMay 16, 2022 | nasdaq.comComparing Bitcoin Versus Sutro Biopharma Reveals New LowMay 14, 2022 | finance.yahoo.comRevenue Downgrade: Here's What Analysts Forecast For Sutro Biopharma, Inc. (NASDAQ:STRO)May 9, 2022 | finance.yahoo.comSutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated MilestonesSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STRO CUSIPN/A CIK1382101 Webwww.sutrobio.com Phone(650) 392-8412FaxN/AEmployees224Year FoundedN/ACompany Calendar Last Earnings5/09/2022Today6/30/2022Next Earnings (Estimated)8/08/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$24.33 High Stock Price Forecast$30.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+367.1%Consensus RatingBuy Rating Score (0-4)3 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-105.54 million Net Margins-215.16% Pretax Margin-215.16% Return on Equity-42.97% Return on Assets-33.22% Debt Debt-to-Equity Ratio0.06 Current Ratio5.90 Quick Ratio5.90 Sales & Book Value Annual Sales$61.88 million Price / Sales3.95 Cash FlowN/A Price / Cash FlowN/A Book Value$5.46 per share Price / Book0.95Miscellaneous Outstanding Shares46,934,000Free Float44,540,000Market Cap$244.53 million OptionableNot Optionable Beta1.12 Sutro Biopharma Frequently Asked Questions Should I buy or sell Sutro Biopharma stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Sutro Biopharma stock. View analyst ratings for Sutro Biopharma or view top-rated stocks. What is Sutro Biopharma's stock price forecast for 2022? 4 Wall Street analysts have issued 12-month target prices for Sutro Biopharma's stock. Their STRO stock forecasts range from $16.00 to $30.00. On average, they expect Sutro Biopharma's share price to reach $24.33 in the next year. This suggests a possible upside of 367.1% from the stock's current price. View analysts' price targets for Sutro Biopharma or view top-rated stocks among Wall Street analysts. How has Sutro Biopharma's stock price performed in 2022? Sutro Biopharma's stock was trading at $14.88 at the beginning of the year. Since then, STRO stock has decreased by 65.0% and is now trading at $5.21. View the best growth stocks for 2022 here. When is Sutro Biopharma's next earnings date? Sutro Biopharma is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Sutro Biopharma. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma, Inc. (NASDAQ:STRO) released its quarterly earnings data on Monday, May, 9th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by $0.08. Sutro Biopharma had a negative net margin of 215.16% and a negative trailing twelve-month return on equity of 42.97%. View Sutro Biopharma's earnings history. Who are Sutro Biopharma's key executives? Sutro Biopharma's management team includes the following people: Mr. William J. Newell J.D., CEO & Director (Age 64, Pay $1.06M)Mr. Edward C. Albini, CFO & Sec. (Age 64, Pay $596.4k)Dr. Trevor J. Hallam, Pres of Research & Chief Scientific Officer (Age 63, Pay $882.83k)Dr. Arturo M. Molina FACP, M.D., M.S., MS, Chief Medical Officer (Age 63, Pay $691.83k)Ms. Jane Chung R.Ph., Chief Commercial Officer (Age 51, Pay $832.52k)Dr. James R. Swartz Ph.D., Sc.D., FounderDr. Shabbir T. Anik, Chief Technical Operations Officer (Age 69)Ms. Annie J. Chang M.B.A., VP of Investor RelationsMr. David Pauling J.D., M.A., Gen. CounselMs. Linda A. Fitzpatrick, Chief People & Communications Officer (Age 65) What is William J. Newell's approval rating as Sutro Biopharma's CEO? 11 employees have rated Sutro Biopharma CEO William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among Sutro Biopharma's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Sutro Biopharma's key competitors? Some companies that are related to Sutro Biopharma include Replimune Group (REPL), Alector (ALEC), Editas Medicine (EDIT), Arcellx (ACLX), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), iTeos Therapeutics (ITOS), Atara Biotherapeutics (ATRA), Osiris Therapeutics (OSIR), Sangamo Therapeutics (SGMO), Instil Bio (TIL), NanoString Technologies (NSTG), Cullinan Oncology (CGEM), Coherus BioSciences (CHRS) and Agenus (AGEN). View all of STRO's competitors. What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV). When did Sutro Biopharma IPO? (STRO) raised $75 million in an IPO on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Sutro Biopharma's stock symbol? Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO." How do I buy shares of Sutro Biopharma? Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sutro Biopharma's stock price today? One share of STRO stock can currently be purchased for approximately $5.21. How much money does Sutro Biopharma make? Sutro Biopharma (NASDAQ:STRO) has a market capitalization of $244.53 million and generates $61.88 million in revenue each year. The company earns $-105.54 million in net income (profit) each year or ($2.47) on an earnings per share basis. How many employees does Sutro Biopharma have? Sutro Biopharma employs 224 workers across the globe. How can I contact Sutro Biopharma? Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The official website for Sutro Biopharma is www.sutrobio.com. The company can be reached via phone at (650) 392-8412 or via email at [email protected]. This page (NASDAQ:STRO) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
